PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
PRECIGEN, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$6.66+0.28 (+4.31%)
Close on Oct 19, 2026
- Market cap
- $2.76B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
-1141.1%
Net margin
-2588.2%−2055.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +146.7% | -28.9% | -21.3% | -25.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -29.8% | -245.6% | -843.6% | |
| Return on assets | -19.3% | -44.3% | -166.7% | |
| Current ratio | 3.33 | 3.54 | 3.09 | |
| Debt to equity | 0.01 | 2.56 | 4.46 | |
| Net debt to EBITDA | 0.61× | – | -0.59× | |
| Interest coverage | -145.4× | – | -28.6× | |
| Capex to revenue | 16.6% | 23.5% | 20.6% | |
| Diluted shares | 118M | 167M | 313M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Precigen generated $343.75M from operations and spent $24.29M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$343.75M
Used
$24.29M
Capital expenditure$24.29M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2588.2%
×Asset turnover0.06×
×Equity multiplier5.06×
=Return on equity, FY2025-843.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -2588.2% | 0.06× | 5.06× | -843.6% |
| FY2024 | -3216.2% | 0.03× | 1.89× | -160.8% |
| FY2023 | -1540.6% | 0.03× | 1.50× | -78.4% |
| FY2022 | 105.2% | 0.09× | 2.46× | 24.2% |
| FY2021 | -646.0% | 0.04× | 3.86× | -105.6% |
| FY2020 | -533.0% | 0.08× | 5.55× | -245.6% |
| FY2019 | -355.3% | 0.15× | 2.70× | -148.3% |
| FY2018 | -336.9% | 0.19× | 1.74× | -113.6% |
| FY2017 | -53.3% | 0.24× | 1.64× | -21.4% |
| FY2016 | -97.7% | 0.20× | 1.54× | -29.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$250.64M
- Cash generatingOperating cash flow above zero-$87.83M
- Return on assets improvedROA up on the prior year-83.6% → -172.5%
- Earnings backed by cashOperating cash flow above net income-$87.83M vs -$250.64M
- Less leverageLong-term debt to assets fell0.0% → 59.9%
- Better liquidityCurrent ratio rose4.76 → 3.09
- No dilutionShare count did not rise268M → 313M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.03 → 0.07